Ponatinib Linked With Better Outcomes Than Imatinib in Philadelphia Chromosome-Positive ALL
The phase 3 PhALLCON trial showed a trend toward improved EFS in patients with Ph+ newly diagnosed ALL when treated with ponatinib compared with imatinib.
Diagnosis & Disease Information
Recombinant Erwinia Asparaginase Is Efficacious in Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Researchers sought to determine whether JZP458 could maintain adequate nadir serum asparaginase activity in patients with ALL/LBL.
Texas-Mexico Border Residence Linked to Worse Survival in Children With ALL
Living along the Texas-Mexico border is associated with worse survival in children diagnosed with acute lymphoblastic leukemia.
Responses Fleeting With CAR-T Reinfusion in Children, AYAs With B-ALL
Reinfusion with the CAR T-cell therapy tisagenlecleucel does not produce durable remissions in children and AYAs with B-ALL, a study suggests.
CAR-T Survival Outcomes Unrelated to Household Poverty and Neighborhood Opportunity in ALL
Researchers sought to determine whether OS rates with CAR-T therapy were linked to household poverty and neighborhood opportunity for patients with ALL.
Link Discovered Between Congenital Cytomegalovirus Infection and Hyperdiploid Acute Lymphoblastic Leukemia
Researchers sought to determine if there is a link between congenital cytomegalovirus infection and risk of hyperdiploid ALL in pediatric patients.
Substantial Variability Exists in International Consensus Definitions for Pediatric ALL Trial Outcomes
Researchers sought to address the variability in definitions for key outcomes in trials involving pediatric ALL.
Race, Ethnicity, Obesity Have No Significant Impact on CAR-T Therapy Efficacy in B-Cell Acute Lymphoblastic Leukemia
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR-T therapy in patients with B-ALL.
Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Blinatumomab-Based Consolidation Deemed New Standard Care for Adults With MRD-Negative B-ALL
Blinatumomab-based consolidation is a new standard of care for ALL patients with MRD negativity after induction and intensification, researchers say.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...